See more : Zordix AB (publ) (ZORDIX-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Inotiv, Inc. (NOTV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inotiv, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- SWASTIK SAFE DEPOSIT & INVESTM (ZSWASTSA.BO) Income Statement Analysis – Financial Results
- ASR Nederland N.V. (ASRNL.AS) Income Statement Analysis – Financial Results
- Field Trip Health & Wellness Ltd. (FTHWF) Income Statement Analysis – Financial Results
- National Bank of Greece S.A. (ETE.AT) Income Statement Analysis – Financial Results
- China National Medicines Corporation Ltd. (600511.SS) Income Statement Analysis – Financial Results
Inotiv, Inc. (NOTV)
About Inotiv, Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 490.74M | 572.43M | 547.66M | 89.61M | 60.47M | 43.62M | 26.35M | 24.24M | 20.44M | 22.70M | 24.58M | 22.07M | 28.21M | 33.14M | 28.78M | 31.78M | 41.70M | 45.25M | 43.05M | 42.40M | 37.15M | 29.84M | 26.51M | 25.27M | 19.22M | 19.90M | 18.20M | 14.90M |
| Cost of Revenue | 379.57M | 406.98M | 390.44M | 59.45M | 42.23M | 30.70M | 18.23M | 16.55M | 16.02M | 15.21M | 16.62M | 15.01M | 21.37M | 22.64M | 21.45M | 24.18M | 26.36M | 31.45M | 29.24M | 27.05M | 25.62M | 19.43M | 15.95M | 13.15M | 10.58M | 9.20M | 7.60M | 5.80M |
| Gross Profit | 111.17M | 165.44M | 157.21M | 30.16M | 18.24M | 12.92M | 8.12M | 7.70M | 4.43M | 7.49M | 7.96M | 7.06M | 6.84M | 10.51M | 7.33M | 7.60M | 15.33M | 13.79M | 13.81M | 15.34M | 11.53M | 10.41M | 10.56M | 12.12M | 8.64M | 10.70M | 10.60M | 9.10M |
| Gross Profit Ratio | 22.65% | 28.90% | 28.71% | 33.65% | 30.16% | 29.62% | 30.81% | 31.75% | 21.65% | 32.99% | 32.39% | 31.97% | 24.24% | 31.70% | 25.48% | 23.92% | 36.77% | 30.48% | 32.08% | 36.19% | 31.05% | 34.89% | 39.84% | 47.95% | 44.95% | 53.77% | 58.24% | 61.07% |
| Research & Development | 0.00 | 0.00 | 0.00 | 405.00K | 950.00K | 627.00K | 596.00K | 465.00K | 496.00K | 715.00K | 658.00K | 454.00K | 542.00K | 534.00K | 546.00K | 762.00K | 781.00K | 881.00K | 1.44M | 1.33M | 1.10M | 1.33M | 1.52M | 1.61M | 1.81M | 2.00M | 2.20M | 1.60M |
| General & Administrative | 77.03M | 108.23M | 82.44M | 30.38M | 16.98M | 9.53M | 5.97M | 4.90M | 4.58M | 5.07M | 4.94M | 4.41M | 5.52M | 5.56M | 6.12M | 7.67M | 11.73M | 10.43M | 14.73M | 12.78M | 10.18M | 8.28M | 7.42M | 7.02M | 6.39M | 6.50M | 6.80M | 5.90M |
| Selling & Marketing | 20.88M | 19.09M | 16.65M | 3.52M | 3.37M | 2.91M | 1.54M | 1.05M | 1.42M | 1.40M | 1.66M | 1.37M | 3.26M | 3.12M | 2.67M | 3.30M | 3.91M | 2.78M | 0.00 | 0.00 | 0.00 | 2.85B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 97.92M | 127.32M | 99.09M | 33.89M | 20.35M | 12.45M | 7.51M | 5.95M | 6.00M | 6.47M | 6.60M | 5.77M | 8.79M | 8.69M | 8.78M | 10.97M | 11.73M | 10.43M | 14.73M | 12.78M | 10.18M | 8.28M | 7.42M | 7.02M | 6.39M | 6.50M | 6.80M | 5.90M |
| Other Expenses | 99.66M | 119.59M | 85.57M | 1.48M | 15.00K | 9.00K | 6.00K | 5.00K | 6.00K | 5.00K | 9.00K | 7.00K | 12.00K | 0.00 | 0.00 | 472.00K | 24.00K | 92.00K | 1.06M | -21.43K | 0.00 | 0.00 | 0.00 | 0.00 | 1.64M | 1.30M | 900.00K | 500.00K |
| Operating Expenses | 197.58M | 246.90M | 184.66M | 35.77M | 21.30M | 13.07M | 8.10M | 6.42M | 6.49M | 7.19M | 7.25M | 6.23M | 9.33M | 9.22M | 9.33M | 11.73M | 12.54M | 11.40M | 17.23M | 14.08M | 11.28M | 9.61M | 8.94M | 8.63M | 9.83M | 9.80M | 9.90M | 8.00M |
| Cost & Expenses | 577.15M | 653.89M | 575.10M | 95.22M | 63.53M | 43.77M | 26.33M | 22.96M | 22.51M | 22.39M | 23.88M | 21.24M | 30.70M | 31.86M | 30.78M | 35.91M | 38.90M | 42.86M | 46.47M | 41.14M | 36.90M | 29.04M | 24.89M | 21.78M | 20.42M | 19.00M | 17.50M | 13.80M |
| Interest Income | 0.00 | 0.00 | 29.70M | 1.68M | 1.49M | 642.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 46.88M | 43.02M | 29.70M | 1.68M | 1.49M | 642.00K | 274.00K | 375.00K | 399.00K | 287.00K | 488.00K | 649.00K | 714.00K | 706.00K | 1.03M | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 57.12M | 54.72M | 49.32M | 7.56M | 4.98M | 2.72M | 1.86M | 1.68M | 1.56M | 1.41M | 1.60M | 1.72M | 2.28M | 2.13M | 2.32M | 2.65M | 3.01M | 3.46M | 3.89M | 3.44M | 3.44M | 2.68M | 2.04M | 1.76M | 1.64M | 1.30M | 900.00K | 500.00K |
| EBITDA | -26.76M | -26.51M | -273.42M | 15.37M | 1.03M | 2.57M | 1.88M | 2.96M | -1.29M | 1.71M | 1.02M | 2.55M | -3.40M | 3.43M | 327.00K | -1.95M | 5.81M | 2.39M | 366.00K | 4.72M | 3.67M | 3.48M | 3.67M | 5.25M | 444.11K | 2.20M | 1.60M | 1.60M |
| EBITDA Ratio | -5.45% | -4.63% | -6.83% | 8.71% | -5.04% | -0.33% | 0.08% | 5.29% | -10.09% | 1.36% | 9.41% | 3.79% | -8.79% | 10.32% | 1.13% | -4.66% | 13.97% | 13.12% | 3.53% | 11.04% | 9.75% | 10.07% | 13.38% | 20.67% | 2.74% | 10.55% | 8.24% | 10.74% |
| Operating Income | -86.41M | -81.46M | -27.45M | 1.53M | -3.06M | -153.00K | 14.00K | 1.28M | -3.04M | 909.00K | 334.00K | 830.00K | -5.69M | 1.29M | -2.00M | -4.60M | 2.79M | 2.39M | -3.42M | 1.26M | 254.00K | 800.00K | 1.63M | 3.49M | -1.19M | 900.00K | 700.00K | 1.10M |
| Operating Income Ratio | -17.61% | -14.23% | -5.01% | 1.71% | -5.07% | -0.35% | 0.05% | 5.27% | -14.87% | 4.00% | 1.36% | 3.76% | -20.16% | 3.88% | -6.94% | -14.47% | 6.70% | 5.28% | -7.95% | 2.97% | 0.68% | 2.68% | 6.14% | 13.81% | -6.20% | 4.52% | 3.85% | 7.38% |
| Total Other Income/Expenses | -44.35M | -42.78M | -89.00M | 501.00K | -1.48M | -633.00K | -268.00K | -370.00K | -204.00K | 205.00K | -1.40M | -41.00K | -702.00K | -694.00K | -1.03M | -1.06M | -971.00K | -891.00K | -2.67M | -933.00K | -832.29K | -229.00K | -79.29K | -383.49K | -621.01K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -130.76M | -124.24M | -352.45M | 6.12M | -4.54M | -786.00K | -254.00K | 908.00K | -3.24M | 1.11M | -1.06M | 789.00K | -6.39M | 593.00K | -3.02M | -5.66M | 1.82M | 1.50M | -4.44M | 291.39K | -607.00K | 570.58K | 1.55M | 3.11M | -1.81M | 900.00K | 700.00K | 1.10M |
| Income Before Tax Ratio | -26.65% | -21.70% | -64.36% | 6.83% | -7.50% | -1.80% | -0.96% | 3.75% | -15.87% | 4.91% | -4.32% | 3.58% | -22.65% | 1.79% | -10.51% | -17.81% | 4.37% | 3.31% | -10.30% | 0.69% | -1.63% | 1.91% | 5.84% | 12.29% | -9.43% | 4.52% | 3.85% | 7.38% |
| Income Tax Expense | -21.88M | -19.34M | -15.19M | -4.78M | 147.00K | 4.00K | -60.00K | 24.00K | -14.00K | 25.00K | 7.00K | 16.00K | 2.00K | 50.00K | -333.00K | -197.00K | 1.33M | 573.00K | -1.83M | 392.39K | -403.00K | 483.27K | 480.99K | 1.34M | -431.30K | 300.00K | 300.00K | 400.00K |
| Net Income | -108.45M | -105.14M | -337.26M | 10.90M | -4.69M | -790.00K | -194.00K | 884.00K | -3.23M | 1.09M | -1.07M | 773.00K | -6.39M | 543.00K | -2.69M | -5.46M | -1.49M | 926.00K | -2.61M | -101.00K | -203.00K | 87.31K | 1.07M | 1.77M | -1.38M | 600.00K | 400.00K | 700.00K |
| Net Income Ratio | -22.10% | -18.37% | -61.58% | 12.16% | -7.75% | -1.81% | -0.74% | 3.65% | -15.80% | 4.80% | -4.35% | 3.50% | -22.65% | 1.64% | -9.35% | -17.19% | -3.57% | 2.05% | -6.06% | -0.24% | -0.55% | 0.29% | 4.02% | 6.99% | -7.19% | 3.02% | 2.20% | 4.70% |
| EPS | -5.89 | -4.10 | -13.85 | 0.83 | -0.43 | -0.08 | -0.02 | 0.11 | -0.40 | 0.14 | -0.13 | 0.10 | -0.89 | -0.74 | -0.55 | -1.11 | -0.30 | 0.19 | -0.53 | -0.02 | -0.04 | 0.01 | 0.23 | 0.39 | -0.30 | 0.13 | 0.10 | 0.30 |
| EPS Diluted | -5.89 | -4.10 | -13.85 | 0.79 | -0.43 | -0.08 | -0.02 | 0.10 | -0.40 | 0.07 | -0.13 | 0.09 | -0.89 | -0.74 | -0.55 | -1.11 | -0.30 | 0.19 | -0.53 | -0.02 | -0.04 | 0.01 | 0.23 | 0.38 | -0.30 | 0.12 | 0.09 | 0.21 |
| Weighted Avg Shares Out | 25.90M | 25.64M | 24.35M | 13.19M | 10.85M | 10.38M | 8.77M | 8.18M | 8.11M | 8.08M | 7.96M | 7.66M | 7.16M | 5.67M | 4.92M | 4.92M | 4.91M | 4.91M | 4.88M | 4.87M | 4.86M | 4.66M | 4.58M | 4.56M | 4.55M | 4.51M | 4.12M | 4.39M |
| Weighted Avg Shares Out (Dil) | 25.90M | 25.64M | 24.35M | 13.87M | 10.85M | 10.38M | 8.77M | 8.73M | 8.11M | 8.79M | 7.96M | 8.37M | 7.16M | 5.67M | 4.92M | 4.92M | 4.97M | 4.96M | 4.88M | 4.87M | 4.86M | 4.67M | 4.63M | 4.60M | 4.55M | 4.68M | 4.40M | 4.39M |
Inotiv, Inc. (NOTV) Q4 2024 Earnings Call Transcript
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update
Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024
Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity
Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference
Inotiv, Inc. (NOTV) Q3 2024 Earnings Call Transcript
Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates
Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024
3 Breakout Stocks to Buy Before They Make Headlines
Source: https://incomestatements.info
Category: Stock Reports